BioWorld

Aug. 9, 2006

Inspire Terminating Phase II Trial Of INS50589 Antiplatelet

Inspire Pharmaceuticals Inc. may have hit the end of the road for a Phase II product designed for use in cardiopulmonary bypass procedures. (BioWorld Today) Read More

Neurocrine, Valentis Dropping Staff In Wake Of Drug Failures

After Knocking Out Genes, Rye Grass Pollen Made Sneeze-Free

Genizon Signs Genentech To Use Crohn's GeneMap

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...